Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pfizer (PFE) and Actinium Pharmaceuticals (ATNM).
Pfizer (PFE)
RBC Capital analyst Randall Stanicky maintained a Hold rating on Pfizer yesterday and set a price target of $42.00. The company’s shares closed last Tuesday at $37.04.
According to TipRanks.com, Stanicky is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -2.4% and a 39.0% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Osmotica Pharmaceuticals, Pacira Pharmaceuticals, and Aquestive Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $41.83 average price target, representing a 13.4% upside. In a report issued on December 21, Morgan Stanley also maintained a Hold rating on the stock with a $40.00 price target.
See today’s analyst top recommended stocks >>
Actinium Pharmaceuticals (ATNM)
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Actinium Pharmaceuticals, with a price target of $40.00. The company’s shares closed last Tuesday at $8.04.
According to TipRanks.com, Roy is a top 100 analyst with an average return of 57.8% and a 62.3% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Monopar Therapeutics Inc.
Currently, the analyst consensus on Actinium Pharmaceuticals is a Strong Buy with an average price target of $38.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
